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Sounak Gupta, Barbara McGrath, and Douglas R. Cavener
OBJECTIVE—Loss-of-function mutations in Perk (EIF2AK3)
result in permanent neonatal diabetes in humans (Wolcott-
Rallison Syndrome) and mice. Previously, we found that diabetes
associated with Perk deﬁciency resulted from insufﬁcient prolif-
eration of -cells and from defects in insulin secretion. A
substantial fraction of PERK-deﬁcient -cells display a highly
abnormal cellular phenotype characterized by grossly distended
endoplasmic reticulum (ER) and retention of proinsulin. We
investigated over synthesis, lack of ER-associated degradation
(ERAD), and defects in ER to Golgi trafﬁcking as possible causes.
RESEARCH DESIGN AND METHODS—ER functions of
PERK were investigated in cell culture and mice in which Perk
was impaired or gene dosage modulated. The Ins2
/Akita mutant
mice were used as a model system to test the role of PERK in
ERAD.
RESULTS—We report that loss of Perk function does not lead to
uncontrolled protein synthesis but impaired ER-to-Golgi antero-
grade trafﬁcking, retrotranslocation from the ER to the cyto-
plasm, and proteasomal degradation. PERK was also shown to be
required to maintain the integrity of the ER and Golgi and
processing of ATF6. Moreover, decreasing Perk dosage surpris-
ingly ameliorates the progression of the Akita mutants toward
diabetes.
CONCLUSIONS—PERK is a positive regulator of ERAD and
proteasomal activity. Reducing PERK activity ameliorates the
progression of diabetes in the Akita mouse, whereas increasing
PERK dosage hastens its progression. We speculate that PERK
acts as a metabolic sensor in the insulin-secreting -cells to
modulate the trafﬁcking and quality control of proinsulin in the
ER relative to the physiological demands for circulating insulin.
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D
ysfunctions in insulin synthesis and secretion
causes or contributes to all forms of diabetes,
and understanding the underlying molecular
pathology of these dysfunctions has been a
dominant focus in diabetes research. Studies on the regu-
lation of insulin synthesis and secretion have largely
focused on the initial stages of synthesis and the mecha-
nisms of stimulated insulin secretion, but much less is
known about the intervening regulation of proinsulin
maturation and trafﬁcking that occurs in the secretory
pathway organelles including the endoplasmic reticulum
(ER) and Golgi complex (1–4). Proinsulin is cotranslation-
ally translocated into the lumen of the ER, where it is
initially folded and intramolecular disulﬁde bonds are
formed (4,5). Proinsulin must pass a rigorous quality-
control system in the ER before advancing to the Golgi and
secretory granules, where the C-peptide is removed and
mature insulin is packaged into secretory vesicles.
A deﬁciency of PERK in humans is the cause of the
Wolcott-Rallison Syndrome (WRS), which includes perma-
nent neonatal diabetes (6). Loss-of-function mutations of
the mouse Perk gene result in the same syndrome of traits
seen in human WRS, including permanent neonatal diabe-
tes, exocrine pancreas atrophy, osteopenia, growth retar-
dation, and recurrent hepatitis (7–12). Initial studies
showed that diabetes was caused by insulin insufﬁciency
associated with low -cell mass at the time overt diabetes
appeared during neonatal development. By using tissue-
speciﬁc Perk knockout and rescue strains, we established
that expression of the Perk gene in the -cells is required
for the normal proliferation responsible for the rapid
accretion of -cell mass during embryonic and neonatal
development and is required for normal insulin synthesis
and secretion. Critically, we found that expression of Perk
only in the -cells rescues the diabetes and -cell defects
(7,11). These studies also found that the initial claims (8,9)
that low -cell mass was caused by dysfunctions in the ER
stress response and -cell death were incorrect (11);
however, the cause of the multiple defects seen within
-cells was not established. Among the defects observed
in Perk-deﬁcient -cells, the most apparent is a massive
accumulation and retention of proinsulin in the ER that is
ﬁrst seen during fetal development immediately after
endocrine progenitor cells begin to differentiate into insu-
lin-expressing -cells (11). The aberrant accumulation of
proinsulin in the ER could be caused by a number of
possible defects including dysfunctions in quality control,
proinsulin trafﬁcking, or uncontrolled protein synthesis.
RESEARCH DESIGN AND METHODS
Antibodies. The following antibodies were used: golgin 97 (Abcam), GM130
(BD Biosciences), FK2 (Biomol), HA (Cell Signaling), V5 (Invitrogen), insulin
(Linco), proinsulin (Beta Cell Biology Consortium and Hytest), proinsulin
C-peptide (Millipore), c-myc 9E10, glucagon (Santa Cruz), ERGIC-53 (p58),
green ﬂuorescent protein, -tubulin (Sigma), calnexin, and Erp72 (Stressgen).
The CT-A antibody was a gift from the Lencer Lab, and the C8 proteasome
subunit antibody (AbC8) was a gift from the Monaco Lab. The in situ cell death
detection kit, TMR Red (Roche), was used to detect transferase-mediated
dUTP nick-end labeling (TUNEL) cells.
Cell culture, cloning, and transfections. Vesicular stomatitis virus G-
protein (ts045-VSVG-GFP) in pcDNA3.1 was provided by Jennifer Lippincott-
Schwartz (41). Human wild-type proinsulin and the human C(B19)A proinsulin
mutant in pcDNA3.1 were from Peter Arvan (42). The pCMVshort-EYFP-
ATF6 in pEYFO-C1 was provided by Kazutoshi Mori (43), pCGN-HA-S2P was
obtained from Ron Prywes (18), and C terminus deleted 9E10-tagged mouse
PERK (DNPerk) in pcDNA was provided by David Ron (44). Transduction of
cells with DNPerk reduces phosphorylation of eIF2 to 26% normal (13)
similar to the reduction seen in Perk KO pancreata (9). Wild-type and mutant
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terminus. The wild-type proinsulin-KDEL construct was generated by insert-
ing a KDEL ER-retention sequence 3 to the V5 epitope-tag. A small-interfering
RNA (siRNA) directed against human Perk mRNA coding region nucleotides
2,237–2,255 was used to knockdown PERK (45) in human-derived cells lines.
Standard transfection protocols were followed (31,45). AD293 and HepG2
cells were cultured in high-glucose DMEM and 10% FBS at 37°C in 5% CO2.A
short-hairpin RNA directed against the rat Perk mRNA (shPerk) and scramble,
randomized sequence (shScram) were from Fumihiko Urano (Program in
Gene Function and Expression, University of Massachusetts). The shPerk and
shScram are stably integrated into the genome of INS1 832/13 -cell lines and
under the inducible regulation of doxycycline.
Proinsulin and protein synthesis. Proinsulin synthesis was determined as
previously described (8). For protein synthesis islets or cultured cells were
labeled with S
35 labeled Met/Cys (500 Ci/ml) at 37°C for 30 min, precipitated
with 10% trichloroacetic acid. Radioactivity was measured by scintillation
counting and normalized to protein content.
20S proteasomal and retrotranslocation assays. Chymotryptic activity of
the proteasome in cell lysates was determined using the 20S Proteasome
Activity Assay Kit (Chemicon) (46). The cleavage of LLVY-AMC and release of
ﬂuorigenic AMC was measured (360/460 nm) to determine relative protea-
some activity. Retrotranslocation assays were performed as previously de-
scribed (21). Cholera toxin (CT) A (CTA) and CTA1 CT subunits were
detected by Western blot.
Trafﬁcking assays. For trafﬁcking assays ts045 VSVG-GFP was transfected
into cells. At 8 h posttransfection, cells were transferred to the restrictive
temperature of 40°C for 16 h followed by a shift to the permissive temperature
of 32°C for 15 min (unless otherwise speciﬁed). Cells were then harvested for
immunoﬂuorescence, subcellular fractionation, and EndoH assays (47). The
VSVG protein was detected using an antibody to the GFP-tag.
Genetic strains. The Perk KO mice strains (9) were congenic for C57BL/6J or
129SvEvTac or were of mixed background, and each strain exhibited the
defects described herein. To increase the Perk dosage in the -cells of Perk
KO mice, a Perk transgene under the control of the rat insulin promoter
(Perk) was introduced (7). Mice bearing the Akita mutation in a C57BL/6J
background were from The Jackson Laboratories. These mice were crossed
into Perk
/, Perk mice to generate the strains used. The Akita mutants
(C57BL/6J) were crossed with Perk
/ in the 129SvEvTac background to
generate Ins2
/Akita, Perk
/ double heterozygotes or Ins2
/Akita, Perk
/
mice that were F1 hybrids. All other strains were in a mixed genetic
background. All animal studies were approved by the institutional animal care
and use committee of Pennsylvania State University.
Islet isolation. Islets were isolated using a modiﬁed histopaque-1077 sepa-
ration method (11). Islets were cultured in RPMI for 6–12 h at 37°C in 5% CO2
prior to experimental processing.
In vivo glucose-stimulated insulin secretion and total pancreatic insu-
lin content. For studies of in vivo glucose-stimulated insulin secretion
(GSIS), serum was collected after a 16-h fast and 20 min after the intraperi-
toneal injection of 2 mg glucose/g body wt. Serum insulin concentrations were
determined by immunoassay (Meso Scale Discovery). For total pancreatic
insulin measurement, pancreata were sonicated in 1 ml of acid ethanol (95%
ethanol:10.2N HCl in a 50:1 ratio), incubated overnight at 4°C, centrifuged and
the supernatant assayed for insulin.
Statistical analysis. Statistical analysis was performed using Student t test,
and P  0.05 was accepted as signiﬁcant. Error bars represent the SE of the
mean.
RESULTS
PERK-deﬁcient mice exhibit abnormal -cell mor-
phology but normal steady-state protein synthesis
rates. In wild-type -cells (Fig. 1A and B), proinsulin was
found to be localized in a perinuclear pattern within the
Golgi (Fig. 1C), as previously reported (5). A substantial
fraction (ca 30–40%) of PERK-deﬁcient -cells exhibit an
extremely distorted cellular morphology (Fig. 1D–F),
which we denote as an impacted-ER phenotype character-
ized by expanded ER and massive accumulation of proin-
sulin (Fig. 1F, arrows) colocalizing with ER markers (11).
Quantitative analysis of the signal intensity in wild-type,
knockout nonimpacted-, and knockout impacted-ER
-cells revealed that insulin was not signiﬁcantly different
(Fig. 1G). Proinsulin levels were not signiﬁcantly different
between wild-type and Perk KO nonimpacted-ER -cells;
however, the proinsulin level in the Perk KO impacted-ER
-cells is more than sevenfold higher compared with
wild-type or Perk KO nonimpacted-ER -cells. Develop-
mental studies by us have suggested that the impacted-ER
-cells in Perk KO mice are derived from nonimpacted-ER
-cells (11).
To determine whether uncontrolled synthesis caused
overaccumulation of proinsulin in the Perk KO impact-
ed-ER -cell, we examined protein or proinsulin synthesis
rates in PERK-deﬁcient cells. We found that global protein
synthesis rates in INS1-832/13 (13) and AD293-expressing
DNPerk, Perk KO islets (Fig. 1H), and shPerk-expressing
INS1-832/13 -cells (Fig. 1I) were not signiﬁcantly different
from wild-type controls. In addition, proinsulin synthesis
is actually somewhat reduced in shPerk INS1-832/13
-cells (Fig. 1I). Therefore, the abnormal accumulation of
proinsulin in the ER is not caused by uncontrolled or
derepressed proinsulin synthesis and is not correlated
with an increase in general protein synthesis. Moreover,
insulin and proinsulin content in the Perk KO nonimpacted
-cells are not elevated (Fig. 1G) as would be expected if
proinsulin synthesis was derepressed.
Suppression of PERK activity leads to an ER-Golgi
anterograde trafﬁcking defect. Abnormal accumulation
of proinsulin in the ER of PERK-deﬁcient -cells could be
caused by defects in ER-Golgi trafﬁcking, and to address
this question we assessed the trafﬁcking of the tempera-
ture-sensitive variant of the ts045 VSVG-GFP (14) in cells
in which PERK activity was suppressed by a dominant-
negative mutation of Perk (DNPerk). We found that sup-
pressing PERK activity in HepG2 (Fig. 2A–D), INS-1 832/13
(Fig. 2E–H) and AD293 (Fig. 2I–R, supplementary Fig.
S1E, available at http://diabetes.diabetesjournals.org/cgi/
content/full/db09-1064/DC1) cells blocked anterograde
movement of ts045 VSVG-GFP from the ER to the Golgi
compared with vector-transfected control cells (supple-
mentary Fig. S1A–D). This trafﬁcking defect was also
conﬁrmed using the EndoH-resistance assay in AD293
cells (Fig. 2S), which showed an almost complete block in
anterograde trafﬁcking of VSVG following a shift to the
permissive temperature.
Suppression of PERK activity results in redistribu-
tion of Golgi components into the ER. To examine
whether Golgi components were redistributed into the ER in
PERK-suppressed cells as a consequence of the trafﬁcking
defect, we carried out subcellular fractionation (SCF) analy-
sis. For this purpose, AD293 cells cotransfected with ts045
VSVG-GFP and DNPerk were incubated overnight at the
restrictive temperature followed by a shift to the permissive
temperature for 15 min. Equivalent numbers of cells were
then harvested for SCF. In the empty-vector controls, VSVG
was successfully trafﬁcked from the ER-enriched fractions
(fractions 7–9) to the ER-Golgi intermediate compartment
(ERGIC) and partially into the Golgi (Fig. 3A). In contrast, in
the DNPerk cotransfected cells the VSVG cargo was retained
within the ER-enriched fractions (fractions 7–9) (Fig. 3B). In
these cells, the marker for the ERGIC compartment was
redistributed into the ER-enriched fractions, while the Golgi
marker, golgin, showed very low levels of expression relative
to the ER marker calnexin (Fig. 3B).
Immunohistochemical (IHC) analysis revealed an im-
pacted-ER phenotype due to abnormal ER retention of
misfolded ts045 VSVG-GFP in AD293 cells, in which PERK
activity was suppressed by DNPerk (supplementary Fig.
S1E, arrowheads) (Fig. 2C, G, and K)o rb yPerk siRNA–
mediated knockdown (Fig. 2M and P). In addition, the
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the cytoplasm (Fig. 2B, F, J, N, and Q). Similarly, in Perk
KO impacted-ER -cells, GM130 was no longer condensed
into perinuclear structures but instead was redistributed
throughout the cytoplasm (Fig. 3C–E). The localization of
the ERGIC marker protein ERGIC-53 was examined to
determine whether defects in the intermediate compart-
ment were also present in Perk KO impacted-ER -cells.
We found that in wild-type -cells the ERGIC compartment
forms a previously unidentiﬁed structure that encircles a
large concentration of proinsulin in wild-type -cells (Fig.
3F–H). However, in Perk-deﬁcient impacted-ER -cells, the
ERGIC compartment was dispersed and was no longer in
juxtaposition to proinsulin (Fig. 3I–K, box). In addition, the
level of proinsulin was reduced in the ERGIC compart-
ment in the nonimpacted-ER -cells (Fig. 3I–K, arrows).
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FIG. 1. PERK-deﬁcient mice exhibit an abnormal -cell morphology (A–F) and normal steady-state protein synthesis (G). A: TEM image of a
normal -cell from a P1 wild-type mouse. B: At higher magniﬁcation, the normal laminar morphology of the ER and associated ribosomes can be
seen in the wild-type -cell (arrow). C: IHC image of a normal -cell from a P1 wild-type mouse showing proinsulin (red) within the Golgi and
insulin (green) throughout the cytoplasm. Nuclei are stained with DAPI (blue). Pancreata were isolated, ﬁxed, and prepared for IHC analysis as
previously described (9). D: TEM image of a Perk KO -cell from a P1 mouse. E: At higher magniﬁcation, the overall abnormal ER morphology
(arrow) and frequent ribosome-studded balloon-like structures (arrow head) can be readily detected. F: IHC staining for proinsulin in Perk KO
-cells from a P1 mouse shows a subpopulation of cells with abnormal distribution of proinsulin throughout the cytoplasm that colocalizes with
ER markers (11). G: Quantitative analysis of insulin and proinsulin levels were performed on IHC images of -cells in postnatal day 1 Perk KO
and wild-type littermates. All procedures and reagents for histochemical preparation and image collection were done at the same time under
identical conditions to allow direct comparison of signal density area estimates of insulin and proinsulin between genotypes and individuals. Area
density analysis was performed using NIH Image J on clusters of -cells within islets or on individual -cells so as to exclude other endocrine cell
types. Background subtraction was performed by subtracting nonspeciﬁc pixel density calculated from the adjacent exocrine pancreas. A total
of 16–18 islets were analyzed for two individual littermates per genotype. To compare impacted-ER -cells with nonimpacted-ER -cells in Perk
KO mice, 40 individual -cells each were analyzed. Average pixel densities, after background subtraction, are shown without any form of
normalization. KO Imp, Perk KO, impacted-ER phenotype; KO nImp, Perk KO, nonImpacted-ER phenotype. H: Cells were cultured in 11 mmol/l
glucose prior to the addition of S
35-labeled cysteine and methionine. For AD293 cells Perk () represents empty vector and Perk () represents
cells impaired for Perk activity by DNPerk. For islets Perk () represents wild-type neonatal islets (n  16) and Perk ()( n  8) represents
islets isolated from neonatal Perk KO mice. Differences are not statistically signiﬁcant (P > 0.05). I: Global and proinsulin synthesis was assessed
in INS1 832/13 cells in which Perk was ablated by expression of shPerk as compared with a scramble control (shScram). The level of rat Perk
mRNA and protein were reduced by 60–70% and 56–66%, respectively, at 48 h after the induction of the expression of shRNAs by treatment with
2 mg/ml doxycycline in INS1-832/13 -cells. Cells were pulse-labeled with S
35-labeled cysteine and methionine for 30 min, and cellular extracts
were either TCA precipitated for analysis of global protein synthesis or immunoprecipitated with proinsulin antibody followed by electrophoretic
separation. (A high-quality digital representation of this ﬁgure is available in the online issue.)
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deﬁcient cells. ATF6 positively regulates ERp72 and
GRP78/BiP (15) and also represses insulin gene transcrip-
tion (16) and therefore may be the cause of induction
these two ER chaperones (13) in PERK-deﬁcient -cells as
well as the reduced insulin gene expression that we
reported previously (11). ATF6 is an ER resident protein
that upon induction is trafﬁcked to the Golgi where it is
processed by the site 1 and 2 proteases (S1P and S2P,
respectively) to generate the mature transcriptionally ac-
tive form of ATF6 (17). We observed a constitutive reduc-
tion in full-length ATF6 and induction of the cleaved
nuclear form (Fig. 4). In addition, S2P was found to be
abnormally redistributed into the ER of PERK-suppressed
cells (supplementary Fig. S2). These ﬁndings are consis-
tent with previous reports that redistribution of Golgi
proteases to the ER caused by a pharmacological block in
trafﬁcking can result in constitutive processing of ATF6
(18). Associated with the redistribution of Golgi compo-
nents, we found substantial changes in the lipid composi-
tion of the ER and Golgi (supplementary Fig. S3A and B).
Because overexpression of DNPERK protein may effect
lipid composition and other associated defects in the ER
for reasons other than suppressing PERK activity, these
results need to be conﬁrmed by ablating Perk via siRNA
methods.
ERAD is impaired in PERK-suppressed cells. A large
fraction of all newly synthesized cargo proteins in the ER
fail to attain their native conformation (19), and these
proteins undergo ERAD, which is comprised of three
steps: ER-cytosolic retrotranslocation, ubiquitylation, and,
ﬁnally, proteasome-mediated degradation (20). Retrotrans-
location from the ER to the cytoplasm was examined by
monitoring the fate of CT subunits targeted to the ER (21)
(Fig. 5A). Suppression of PERK in AD293 cells substan-
tially reduced the amount of retrotranslocated CTA1 CT
subunit, suggesting that Perk is necessary for retrotrans-
location activity. ERp72, a protein disulﬁde isomerase-like
chaperone, is localized in the ER and is a negative regula-
tor of retrotranslocation (21). Suppression of PERK activ-
ity in AD293 cells led to a 3.3-fold induction in ERp72
protein levels (Fig. 5B), and this was correlated with the
localization of ERp72 to large balloon-like structures in
impacted-ER -cells (Fig. 1D and E, arrowheads) seen in
Perk KO mice (13).
To examine the fate of proinsulin in the ER, indepen-
dent of anterograde trafﬁcking, we expressed proinsulin
containing an ER retention signal (Ins
-KDEL) (supple-
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FIG. 2. An acute ablation of Perk function leads to an ER to Golgi anterograde trafﬁcking defect. IHC in HepG2 cells (A–D), INS1 (832/13) (E–H),
AD293 cells (I–R), and EndoH resistance assay in AD293 cells (S). A–L: Cells were cultured on Lab-Tec (Nalge Nunc) chamber slides prior to
transfection with DNPerk and ts045 VSVG-GFP followed by IHC analysis of detergent-permeabilized cells (0.2% Triton X 100 in 1  PBS for 10
min at room temperature). Arrowheads show a DNPerk and ts045-VSVG-GFP cotransfected cell following a 16-h incubation at the restrictive
temperature and a 15-min shift to the permissive temperature. Arrows indicate an adjacent control cell transfected with only ts045-VSVG-GFP.
A–D: HepG2 cells were cotransfected with c-myc tagged DNPerk (blue, A) and ts045-VSVG-GFP (green, C) and stained for the Golgi marker
GM130 (red, B). The merged image is seen in D. E–H: INS1 (832/13) cells were cotransfected with c-myc–tagged DNPerk (blue, E) and
ts045-VSVG-GFP (green, G) and stained for the Golgi marker GM130 (red, F). The merged image is seen in H. I–L: AD293 cells were cotransfected
with c-myc–tagged DNPerk (blue, I) and ts045-VSVG-GFP (green, K) and stained for the Golgi marker GM130 (red, J). The merged image is seen
in L. M–R: IHC in AD293 cells. Boxed areas in M and P show cells cotransfected with ts045 VSVG-GFP (green) and Perk siRNA after an 8-h
incubation at the restrictive temperature followed by a 15-min shift to the permissive temperature. Human Perk mRNA was reduced by 41% at
8 h posttransfection of the siRNA. Staining for the Golgi marker GM130 shows a dispersed morphology in red (N and Q) and the merged images
are seen in O and R. S: ts045-VSVG-GFP was cotransfected with either empty vector (Vector) or DNPerk into AD293 cells. Cells were incubated
overnight at the restrictive temperature to allow the VSVG to accumulate in the ER (0). Cells were then shifted to the permissive temperature
to allow the protein to trafﬁc to the Golgi. Cells were harvested for EndoH treatment and Western blots at the indicated time points. The higher
MW form (upper arrow) is the EndoH-resistant Golgi form, while the lower arrow indicates the ER-retained EndoH-sensitive form. (A
high-quality digital representation of this ﬁgure is available in the online issue.)
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Ins
-KDEL with DNPerk into AD293 cells, we noted mul-
tiple high–molecular weight forms that we identiﬁed as
ubiquitylated isoforms of proinsulin (Fig. 5C). We also
found a highly signiﬁcant 3.6-fold increase in the accumu-
lation of Ins
-KDEL in the PERK-suppressed cells com-
pared with the empty-vector cotransfected controls (Fig.
5D), while proinsulin and steady-state protein synthesis
levels in these cells showed no signiﬁcant changes (Fig.
1H–I; supplementary Fig. S4C). This suggests that the
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exposure but seen in longer exposure in cytoplasm). GM130 and DAPI are stained for in Perk KO mice in E. The boxed area (D and E) shows a
representative impacted-ER -cell demonstrating increased calnexin expression (D) and diffuse GM130 staining (D and E). F–K: Staining for
ERGIC-53 (F and I), proinsulin (G and J), and the corresponding merged images (H and K) in islets from wild-type (F–H) and P7 Perk KO (I–K)
islets. Arrows (I-K) show quasinormal ER -cells and the boxed areas show a representative impacted-ER -cell. Quasinormal-ER -cells (arrow,
3J) have dramatically reduced proinsulin signal. (A high-quality digital representation of this ﬁgure is available in the online issue.)
S. GUPTA AND ASSOCIATES
diabetes.diabetesjournals.org DIABETES, VOL. 59, AUGUST 2010 1941abnormal accumulation of proinsulin can occur indepen-
dent of both the anterograde trafﬁcking defect and run-
away protein synthesis. PERK-suppressed cells also
showed a signiﬁcant accumulation of the ubiquitylated
proinsulin isoforms within the ER (supplementary Fig.
S4D). This was seen when AD293 cells were cotransfected
with DNPerk and Ins
-KDEL (55.3% increase) (Fig. 5D,
arrow) or wild-type proinsulin (62% increase) (supplemen-
tary Fig. S4E, arrow), suggesting that they are inefﬁciently
degraded and retained within the ER.
An important step in proteasomal assembly occurs at
the ER membrane through the action of proteasome
maturation protein (POMP) to form the 20S core complex
(22). We found that the amount of the 20S proteasome
precursor was greatly diminished in the impacted-ER
-cells of Perk KO mice (Fig. 6A–D), suggesting that
assembly or synthesis of the proteasome may be nega-
tively impacted. Additionally, proteasomal activity in islets
isolated from neonatal Perk KO mice was found to be
signiﬁcantly repressed by 39% (Fig. 6E) compared with
wild-type littermates, although no reduction in proteaso-
mal activity was found in PERK-suppressed AD293 cells.
Moreover, both an acute ablation of Perk in INS1 (832/13)
-cells (13), as well as a treatment of these cells with the
nonspeciﬁc proteasomal inhibitor MG132 (Fig. 6F and G),
phenocopies the accumulation of proinsulin in the ER that
is indistinguishable from the impacted-ER -cells of Perk
KO mice and DNPerk-832/13 cells.
Modulating Perk gene dosage alters the progression
of Akita insulin mutant mice to frank diabetes. The
Akita-Ins2 mutation (C96Y) in mice leads to the develop-
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FIG. 4. Basal level of processed ATF6 is elevated in Perk-deﬁcient
cells. AD293 cells were cotransfected with EYFP-ATF6 and either an
empty vector (Vector) or DNPerk. Empty-vector cotransfected samples
were either left untreated, while samples treated with 5 mmol/l dithio-
threitol (DTT) or 5 g/ml brefeldin A (BFA) for 1 h served as controls
for ATF6 induction. Immunoblotting with an antibody that recognizes
YFP-tagged ATF6 shows both the ER-resident uncleaved (ﬂ, full
length) and cleaved nuclear (n) forms. Quantiﬁcation of the nuclear
ATF6 expressed as a percentage of the full-length form is shown below
the tubulin panel.
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FIG. 5. Impaired ERAD in Perk-deﬁcient cells. A: Retrotranslocation of CTA1 subunit in PERK-suppressed cells. AD293 cells carrying either
empty vector or DNPerk were incubated with cholera holotoxin for 90 min. Cells were harvested and separated into cytosolic (C) and ER (ER)
fractions and then immunoblotted for calnexin (ER marker), tubulin (cytosolic marker), CTA, or CTA1. Extent of retrotranslocation was
quantiﬁed by expressing cytosolic CTA1 (normalized to tubulin) as a percentage of ER-retained CTA1 (normalized to calnexin). The percent
retrotranslocation in PERK-suppressed cells normalized to empty vector is indicated underneath the immunoblot panels. B: Protein extracts from
AD293 cells transfected with DNPerk or empty vector were immunoblotted for ERp72. Ablation of Perk in AD293 cells resulted in a 3.3-fold
increase in ERp72. C, lane 1: V5-tagged Ins
-KDEL was expressed in AD293 cells and was immunoprecipitated and immunoblotted with anti-V5
antibody. Arrowhead indicates V5-tagged Ins
-KDEL. Lane 2: Untransfected control. Lanes 3 and 4: Ins
-KDEL construct was transfected into
AD293 cells and lysates were immunoprecipitated with anti-V5 and then immunoblotted with the FK2 antibody that recognizes mono- and
polyubiquitylated species but not free ubiquitin. Molecular weight markers (kd) are shown to the right of the blot. D: AD293 cells were
cotransfected with V5-tagged wild-type proinsulin-KDEL (Ins
-KDEL) and empty vector (Vector) or DNPerk. Lysates were immunoblotted with
the anti-V5 antibody. Arrowhead indicates V5-tagged proinsulin. A 3.6-fold increase in the retention of Ins
-KDEL in the PERK-suppressed cells
compared with the empty-vector cotransfected controls was noted. The multiple higher–molecular weight bands (arrow) are ubiquitylated
species as shown in C.
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weeks (23), and the same mutation in the single human
insulin gene results in permanent neonatal diabetes (24).
Unexpectedly, we found that -cell mass was expanded in
Ins2
/Akita heterozygous mice at the time these mice are
rapidly progressing to frank diabetes (Table 1). However,
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TABLE 1
Akita insulin mutant mice exhibit -cell hyperplasia during early progression to diabetes
Genotype Ins2
/ Ins2
/Akita Ins2
/Akita
Perk
/ and
/ Perk
/ and
/ Perk
 Perk
/ and
/
Blood glucose (mg/dl) 136.0 244.1* 297.8†
Average number -cells per islet 29.6 68.7‡ 35.4 (NS)
Percent TUNEL
 -cells 0.37 0.04 0.09
Chop mRNA 100.0  42.7 146.7  48.8 (NS) 150.0  49.4 (NS)
The data shown in this table is representative of mice that belong to the postnatal age group p14–17. Serum blood glucose was determined
in random fed mice. To estimate -cell mass and cell death, tissue sections were immunostained for insulin, TUNEL, and DAPI. -Cells and
insulin-positive cells were manually counted for all islets containing more than ﬁve -cells. The average number of -cells within a
cross-section of each islet was calculated. To estimate -cell death, cells that were insulin and TUNEL positive were manually counted. For
IHC analysis, pancreata were harvested from littermates. The number of mice, islets, and -cells counted were as follows: Ins2
/ Perk
/
and
/, mice 	 6, islets 	 136, and -cells 	 2,172; Ins2
/Akita Perk
/ and
/, mice 	 10, islets 	 277, and -cells 	 12,777; and Ins2
/Akita;
Perk
 Perk
/ and
/, mice 	 6, islets 	 136, and -cells 	 3,492. Chop mRNA level for each genotype was normalized to Ins2
/; Perk
/
and P
/. For Chop mRNA, islets were isolated from littermates (Ins2
/; Perk
/ and
/, n 	 6; Ins2
/Akita; Perk
/ and
/, n 	 2;
Ins2
/Akita; Perk
 Perk
/ and
/, n 	 4). Comparison of means (Student t test) showed no signiﬁcant differences between any of the
paired comparisons for Chop mRNA levels. *P 	 0.055; †P 	 0.0066; ‡P 	 0.00,016 vs. age-matched controls (Ins2
/; Perk
/ and
/). NS,
not signiﬁcant.
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ically reduced in both Ins2
/Akita heterozygotes and
Ins2
Akita/Akita homozygotes compared with robust expres-
sion of glucagon in neighboring -cells (supplementary
Fig. S5). We crossed the Ins2
/Akita heterozygotes with
mice that were also heterozygous for Perk and found that
the double heterozygous (Ins2
/Akita; Perk
/) mice ex-
hibited a substantial delay in developing diabetes com-
pared with the Ins2
/Akita; Perk
/ mice (Fig. 7A).
Increasing Perk gene dosage, speciﬁcally in the -cells of
the Akita heterozygotes, by genetically introducing the
wild-type Perk gene under the control of a truncated rat
Ins2 promoter (Perk) (7), had the opposite effect by
further accelerating the progression to overt diabetes (Fig.
7A). The more rapid progression to diabetes seen in the
Akita homozygous mice was also delayed by reducing
Perk dosage (Fig. 7B). Total pancreatic insulin content
was inversely correlated with serum glucose as a function
of Perk dosage in the Ins2
/Akita mice (Fig. 7C compared
with Fig. 7A). Increasing Perk gene dosage in the -cells of
wild-type Ins2
/ mice (Perk) also decreased pancreatic
insulin content (Fig. 7D) and in vivo GSIS (Fig. 7E). In
vivo GSIS and basal serum insulin was repressed in the
Ins2
/Akita mice independent of Perk genotype (Fig. 7E).
However, no signiﬁcant increase was seen in apparent
-cell death in the Akita mice as assessed by TUNEL
analysis (Table 1), nor was the proapoptotic Chop
(GADD153) gene expression elevated. Even more surpris-
ingly, -cell mass and islet size was signiﬁcantly expanded
in Ins2
/Akita mice (Table 1) during the time that these
mice are rapidly progressing to frank diabetes.
DISCUSSION
The diabetes seen in PERK-deﬁcient humans and mice was
speculated to be caused by dysfunctions in the ER stress
response, including derepressed protein synthesis (8,9).
However, we found that protein synthesis and proinsulin
synthesis is not derepressed in Perk-deﬁcient islets or
other cell types that we have examined (12,13), and the
majority of -cells in Perk KO mice have no increase in
proinsulin and have a signiﬁcant reduction in insulin
content. Therefore, the observed accumulation of proin-
sulin in the PERK-deﬁcient -cells, which exhibit the
impacted-ER phenotype, is not caused by runaway protein
synthesis. Rather, we found severe ablation of ER-Golgi
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FIG. 7. Perk gene dosage modulates diabetic progression of the Akita mouse. A–E: Four Perk genotypes, including Perk
/ (“2”), Perk
/ (“1”),
Perk;Perk
/ (“2”), and Perk;Perk
/ (“1”), were crossed to Ins2
/Akita mice to assess glucose homeostasis and insulin in the resulting
strains. The expression of Perk mRNA is elevated 
80% above normal in Perk;Perk
/ in -cells. A: Progression toward overt diabetes in
Ins2
/Akita mutant is positively correlated with increasing Perk gene dosage. Blood glucose was measured at P23 and P28 in the same group of mice
(2: n  11, 1: n  11, 2: n  45, 1: n  42; *P < 0.05, **P < 0.005, ****P < 0.00005, *******P < 0.00000005). B: Random blood glucose levels
measured in P17 and P23 Ins2
Akita/Akita mutant mice show that higher blood glucose levels are associated with an increase in Perk gene dosage (2:
n  6, 1: n  10; *P < 0.05). C: Pancreatic insulin content decreases with increasing Perk gene dosage in the Ins2
/Akita mice. The insulin content
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/ mice (1 and 2, n  10; 1 and 2, n  8). The difference between mice with and without Perk transgene is statistically
signiﬁcant (*P  0.02). E: An increase in Perk gene dosage was found to lead to an ablation of in vivo GSIS in P28 Ins2
/ mice (1 and 2: n 
12, 1 and 2: n  11; **P < 0.005). P28 Ins2
/Akita littermates demonstrated lower fasting serum insulin levels and impaired GSIS independent of
Perk gene dosage (1 and 2: n  11, 1 and 2: n  10).
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reduced retrotranslocation of proteins out of the ER, and
a decrease in proteasomal activity that together provide an
explanation for the accumulation of proinsulin in the ER
and insulin insufﬁciency.
Possible PERK-dependent factors that impact multiple
ER functions are the chaperone/folding proteins GRP78/
BiP, ERp72, and ERO1. We found that BiP and ERp72 are
substantially increased upon acute ablation of PERK in
832/13 -cells (13) and exhibited enhanced expression in
the impacted-ER -cells in mouse islets, whereas ERO1
is reduced in islets (11,13). Modulating the expression of
these ER chaperones can have a multiplicity of effects
because these proteins are essential for folding, antero-
grade trafﬁcking, and quality control (21,25,26). Increasing
the expression of BiP may result in enhanced retention of
client proteins in the ER by impeding anterograde trafﬁck-
ing and secretion (25). Elevated expression of ERp72 also
increases ER retention and impedes the retrotranslocation
step in ERAD (21). Genetic ablation of ERO1 has recently
been shown to negatively impact glucose homeostasis
(27). We speculate that PERK may regulate the competi-
tive balance among ER chaperones that promotes either
anterograde trafﬁcking or ERAD of client proteins.
Two ﬁndings support the hypothesis that PERK primar-
ily regulates ERAD. First, by tagging proinsulin with an ER
retention signal we reduced the possibility of anterograde
trafﬁcking. Yet, we found that proinsulin still accumulated
at much higher levels in the ER when Perk was impaired,
suggesting that accumulation of proinsulin in Perk KO
-cells is caused by a failure in ERAD rather than antero-
grade trafﬁcking. Second, the impact of altering Perk gene
dosage in the Akita mouse suggests that Perk promotes
ERAD. We found that decreasing Perk gene dosage by half
ameliorates the progression of the Akita mouse to overt
diabetes, whereas increasing Perk gene dosage in the
-cells of the Perk transgenic mouse hastens progression
to diabetes. Initially, it was proposed that increased -cell
death was the cause of the dominant Akita phenotype
(28,29). However, we found substantially higher -cell
mass in Akita mice compared with wild-type at the onset
of diabetes, and we failed to see an increase in TUNEL-
positive -cells. Although -cell mass is not reduced at the
onset of diabetes in Akita mice, insulin secretion is
severely reduced (23). We speculate that the observed
increase in -cell mass is due to a compensatory response
to reduced insulin secretion. Recent studies (30,31) have
suggested that the Ins
Akita allele acts dominantly to en-
hance degradation of both the Akita and wild-type proin-
sulin via the ERAD pathway, and we propose that Perk
acts to modulate the level of wild-type proinsulin degra-
dation stimulated by the Ins
Akita mutation. Under this
hypothesis, reducing Perk gene dosage decreases ERAD,
thus sparing the degradation of wild-type proinsulin;
whereas, increasing PERK dosage enhances the degrada-
tion of wild-type proinsulin, thus reducing secreted insulin
even further.
Two ERAD processes were found to be impaired in
Perk-deﬁcient -cells, retrotranslocation and proteasomal
degradation, which raises the question if they are inter-
connected. Although the proteasome is localized in the
cytoplasm, the 20S precursor is assembled at the ER
membrane (22). ER dysfunctions or stress can impede
proteasomal degradation of proteins (32), and mutations
in proteins that regulate retrotranslocation can also impair
general proteasomal activity (33). In addition to reduced
general proteasomal activity, the 20S proteasome precur-
sor was greatly diminished in the impacted-ER -cells of
Perk KO mice (Fig. 6E), suggesting that assembly or
synthesis of the proteasome may be negatively impacted.
Inhibition of proteasomal activity by MG132 also pheno-
copied the accumulation of proinsulin in the ER observed
in Perk-deﬁcient -cells, consistent with the hypothesis
that Perk may positively regulate ERAD.
Perk deﬁciency also results in dramatic changes in
organelle structure and ER membrane composition in a
substantial fraction of the -cells. The Golgi apparatus,
which normally displays a compact perinuclear localiza-
tion, is dispersed and no longer distinct from the ER. The
activation of the transcription factor ATF6 is also depen-
dent upon the maintenance of ER and Golgi integrity, and
we found that that the processed nuclear form of ATF6
was constitutively expressed in PERK-deﬁcient -cells,
which is most likely due to mislocalization of the Golgi-
processing enzymes S1P and S2P into the ER. This is
consistent with the role of ATF6 as a negative regulator of
insulin gene transcription (16,34) and reduced insulin
mRNA levels in PERK-suppressed -cells in culture (13)
and in neonatal mice (11).
We have previously reported that Perk-deﬁcient mice
have a low -cell mass due to decreased levels of -cell
proliferation during the critical late-embryonic to early
neonatal stages of life (11). Moreover, -cell proliferation
is also reduced in insulinomas of Perk-deﬁcient mice (35).
How might the defects in ER functions and organelle
integrity impact -cell proliferation? First, normal protea-
somal activity is necessary for cell-cycle progression (36),
and we found that proteasomal activity was reduced.
Second, the integrity of the ER and Golgi are normally
maintained at all stages of mitosis (37). The disruption in
the normal subcellular organization of these two or-
ganelles along with the defect in proteasomal activity (36)
likely causes the reduced proliferation of -cells in Perk-
deﬁcient mice.
We speculate that the major function of PERK in the
-cells is to act as a metabolic sensor that regulates
proinsulin degradation in concert with metabolic demand
for insulin. PERK enzymatic activity is negatively regu-
lated by GRP78/BiP, when bound to calcium (38). Disas-
sociation of GRP78/BiP-Ca
2 from PERK results in
dimerization, autophosphorylation, and activation of its
catalytic activity to phosphorylate eIF2 (38,39). PERK
activity can be activated by dynamic changes in ER
calcium that occur during fasting and glucose-stimulated
insulin secretion without ever causing an apparent ER
stress response (9,40). Following a brief fasting period, the
activation of PERK is increased, whereas treatment of
islets in culture with high glucose represses PERK’s activ-
ity. We suggest that the function of PERK is to regulate
proinsulin turnover in response to reduced nutrient intake
when the demand for insulin is reduced.
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